Up-regulation of uncoupling proteins by β-adrenergic stimulation in L6 myotubes  by Nagase, Itsuro et al.
Up-regulation of uncoupling proteins by L-adrenergic stimulation in
L6 myotubes
Itsuro Nagasea, Toshihide Yoshidab, Masayuki Saitoa;*
aDepartment of Biomedical Sciences, Laboratory of Biochemistry, Graduate School of Veterinary Medicine, Hokkaido University,
Sapporo 060-0818, Japan
bFirst Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kyoto 602-8566, Japan
Received 9 March 2001; accepted 15 March 2001
First published online 26 March 2001
Edited by Vladimir Skulachev
Abstract Catecholamine-induced and L-adrenergic receptor (L-
AR)-mediated thermogenesis in skeletal muscle is a significant
component of whole-body energy expenditure. Skeletal muscle
expresses uncoupling protein (UCP) 2 and UCP3, which can
dissipate the transmitochondrial electrochemical gradient and
thereby may be involved in regulation of energy metabolism. We
investigated the effects of L-AR stimulation on UCP2 and UCP3
expression in L6 myotubes. Stimulation of the cells with
epinephrine increased the UCP3 mRNA level transiently at 6 h,
and also the UCP2 mRNA level at 6^24 h. The stimulatory
effects of epinephrine were also observed in the presence of
carbacyclin and 9-cis retinoic acid, and mimicked by isoproter-
enol and salbutamol (L2-AR agonists), but abolished by
propranolol and ICI-118,551 (L2-AR antagonists). Pharmacolo-
gical and mRNA analyses revealed the existence of L2-AR, but
not L1- and L3-ARs, in L6 myotubes. These results suggested
that catecholamines up-regulate UCP2 and UCP3 expression
through direct action on the L2-AR in skeletal muscle. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
L-Adrenergic stimulation increases regulatory energy expen-
diture (thermogenesis) in brown adipose tissue (BAT) and
skeletal muscle in rodents. In BAT, norepinephrine released
from sympathetic nerve endings increases lipolysis and ther-
mogenesis through stimulation of the L-adrenergic receptor
(L-AR) of brown adipocytes [1,2]. A key molecule for BAT
thermogenesis is uncoupling protein (UCP) 1, which is present
exclusively in BAT and dissipates the transmembrane proton
gradient of mitochondria as heat [3]. In contrast to BAT, the
mechanism of regulatory thermogenesis in skeletal muscle is
poorly understood, though it is recognized to contribute to
whole-body energy expenditure more than that of BAT. Re-
cently, two isoforms of UCP, UCP2 and UCP3, were found to
be expressed in skeletal muscle [4^7]. It has been shown that
mRNA expression of muscle UCP2 and UCP3 alters under
various physiological and pathological conditions related to
energy metabolism [8]. Moreover, Clapham et al. reported
that mice overexpressing UCP3 in skeletal muscle are hyper-
phagic and lean [9]. Collectively, it has been proposed, but
not generally accepted, that these new UCP members are in-
volved in the regulation of energy metabolism in skeletal
muscle [10].
Apparently con£icting results have been reported concern-
ing the e¡ects of L-adrenergic stimulation on UCP mRNA
expression in skeletal muscle. For example, cold exposure,
which is the most e¡ective physiological stimulus to activate
the L-AR and to induce BAT UCP1 expression, decreases
[11], does not in£uence [12], or increases [13] muscle UCP3
expression. Administration of agonists of L3-AR decreases,
increases, or does not change the mRNA levels of UCP2
and UCP3 in skeletal muscle [14^17]. These discrepancies
might be due to the di¡erences in rodent species used, dura-
tion of the treatment, and agonists used. In fact, Lin et al. [13]
reported that cold exposure results in a transient increase in
muscle UCP3 mRNA between 6^24 h but a substantial de-
crease after 3^6 days. Moreover, in these in vivo studies, it
was di⁄cult to discriminate the direct action of the L-AR of
muscle from some indirect e¡ects. In fact, cold exposure and
L3-AR agonists cause lipolysis in adipose tissue and elevation
of plasma-free fatty acids, which in turn act as potent stim-
ulators of muscle UCP3 expression [18]. It is thus obvious that
some in vitro system using cultured myotubes and/or isolated
muscle tissue would be useful to examine the direct e¡ects of
adrenergic stimulation, but no such study has been reported
thus far.
Recently, we examined UCP3 mRNA expression in L6
myotubes and demonstrated that UCP3 expression was up-
regulated by triiodothyronine, ligands of peroxisome prolifer-
ator-activated receptor (PPAR) and retinoid X receptor
(RXR) and free fatty acids in vitro [19], consistent with pre-
viously reported in vivo results. Thus, in the present study, we
investigated the e¡ects of L-adrenergic stimulation on UCP2
and UCP3 mRNA expression in the presence or absence
of PPAR and/or RXR ligands using L6 myotubes in culture.
Our results showed that adrenergic stimulation directly
up-regulated UCP2 and UCP3 mRNA expression through
L2-AR.
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2. Materials and methods
2.1. Cell culture
Rat L6 myoblasts (clone L6Y) were kindly provided by Dr. Amira
Klip (Programme in Cell Biology, The Hospital for Sick Children,
Toronto, ON, Canada). They were cultured in Dulbecco’s modi¢ed
Eagle’s medium supplemented with 10% fetal calf serum, 50 units/ml
penicillin and 50 Wg/ml streptomycin at 37‡C, 5% CO2. When the cells
reached con£uence (Day 0), they were di¡erentiated in a medium
containing 2% horse serum (di¡erentiation medium). The fresh di¡er-
entiation medium was substituted at Day 4 and then test substances
dissolved in 0.1% dimethyl sulfoxide were added. L6 myotubes were
cultured further for 3^24 h, and harvested for RNA extraction at Day
5.
2.2. RNA analysis
Total RNA was extracted by the guanidium-thiocyanate method
[20] using ISOGEN (Nippon Gene, Toyama, Japan). For Northern
blot analysis, 30 Wg of total RNA was separated on a 1.2% agarose/
formaldehyde gel and transferred to and ¢xed on a nylon membrane.
DNA fragments used for hybridization probes were: 927-bp and 924-
bp PCR products of rat UCP2 and UCP3 cDNAs, respectively [21],
and a 452-bp PCR product of rat glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH) cDNA. They were labeled with [K-32P]dCTP
using a multiprime DNA labeling kit (Amersham, Buckinghamshire,
UK). The blots were hybridized to the labeled cDNA probes in 0.5 M
sodium phosphate (pH. 6.8), 7% SDS, 1% BSA, 1 mM EDTA and
200 Wg/ml heat-denatured salmon sperm DNA at 65‡C for 12 h,
washed with 2USSC or 0.1USSC at 65‡C, and analyzed with a
bio-imaging analyzer BAS 2000 (Fuji Film, Tokyo, Japan).
mRNA expression of the three L-AR subtypes was examined by
RT-PCR analysis. 1 Wg of total RNA was reverse-transcribed by using
an Advantage RT-for-PCR Kit (Clontech, Palo Alto, CA, USA) for
60 min at 42‡C in a solution of 0.5 mM dNTP mixture, 20 pM
oligo(dT)18 primer, 1 unit/Wl RNase inhibitor and 10 units/Wl
MMLV reverse transcriptase. PCR was carried out at 95‡C for 45
s, 55‡C for 45 s, 72‡C for 2 min for 25 cycles on a GeneAmp PCR
System 9600 (Perkin-Elmer Applied Biosystems, Tokyo, Japan) in a
solution containing 1UAmpliTaq PCR bu¡er, 0.2 mM each dNTP
mix, 0.4 mM primers and 0.04 units/Wl Amplitaq DNA polymerase.
Oligonucleotide primers used were: L1-AR, 5P-411AGACGTGC-
TATGTGTGACGG-3P and 5P-782CAGCTGTCGATCTTCTTCA-
CC-3P ; L2-AR, 5P-64CACGACATCACTCAGGAACG-3P and 5P-
351GACGCACAACACATCAATGG-3P ; L3-AR, 5P-552AGAGTG-
TCACTCCAATCCGC-3P and 5P-1079TAGCTGCAGAGAAGAC-
GACG-3P.
2.3. cAMP assay
L6 myotubes were incubated in Hank’s solution at 37‡C for 10 min
with various concentrations of L-agonists and 0.1 mM 3-isobutyl-1-
methylxanthine. After the reaction was terminated by adding 0.1 N
HCl, cAMP formed was assayed using an enzyme immunoassay kit
(Amersham).
2.4. Chemicals
Epinephrine, isoproterenol, propranolol, carbacyclin, 9-cis retinoic
acid, dibutyryl-cAMP and forskolin were purchased from Sigma (St.
Louis, MO, USA). BRL 37344, CGP-20712A, ICI-118,551 were pur-
chased from RBI (Natick, MA, USA). CL316,243 was provided by
American Cyanamid Co. (Pearl River, NY, USA).
2.5. Data analysis
All experiments were repeated two times, and representative North-
ern blot data are shown in the ¢gures. Values are expressed as means
of two experiments. Data of cAMP accumulation are means þ S.E.M.
for three independent experiments.
3. Results
3.1. Time-dependent e¡ects of epinephrine on UCP2 and
UCP3 mRNA levels in L6 myotubes
Lin et al. [13] reported that the mRNA levels of UCP2 and
UCP3 in skeletal muscle increased transiently after rats were
exposed to cold: that is, the UCP3 mRNA level increased 3-
fold between 6 and 24 h and decreased to 50% of the control
value after 6 days in the cold, whereas the UCP2 mRNA level
doubled on Day 3 and returned to normal after 6 days. To
determine whether similar time-dependent expression of UCPs
is also mimicked by epinephrine in vitro, ¢rst, we measured
the UCP2 and UCP3 mRNA levels in L6 myotubes stimu-
lated by epinephrine for 3^24 h. The UCP2 mRNA level
began to increase at 3 h and reached rather steady levels at
9^24 h (Fig. 1). The UCP3 mRNA level was also increased at
6 h, but decreased to the basal level at 12^24 h. Thus, epi-
nephrine stimulation of L6 myotubes induced mRNA expres-
sion of both UCP2 and UCP3 in 6^24 h. In the following
experiments, L6 myotubes were stimulated by adrenergic ago-
nists for either 6 or 24 h.
3.2. E¡ects of L-AR stimulation on UCP2 and UCP3 mRNA
expression in L6 myotubes
Since mRNA expression of UCP2 and UCP3 in L6 myo-
tubes is known to be up-regulated by ligands of PPAR and
RXR [19,22], we next examined the e¡ects of epinephrine on
the gene expression in the presence or absence of carbacyclin
(a PPAR ligand) and 9-cis retinoic acid (an RXR ligand).
When L6 myotubes were stimulated by epinephrine for 6 h,
the UCP3 mRNA level was remarkably increased even in the
presence of carbacyclin and 9-cis retinoic acid (Fig. 2A). Sim-
ilarly, the UCP2 mRNA level was also increased by 6- and 24-
Fig. 1. Time-dependent e¡ects of epinephrine on UCP2 and UCP3
mRNA expression in L6 myotubes. L6 myotubes were treated for
3^24 h with 1 WM epinephrine, and 30 Wg of total RNA was used
for Northern blot analysis. A: Representative blots. B: The UCP2
and UCP3 mRNA levels were normalized by the GAPDH mRNA
level and represented as relative to 0 h. Values are means of two ex-
periments.
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h stimulation with epinephrine (Fig. 2A,B). In contrast, in the
presence of carbacyclin and 9-cis retinoic acid, the 24-h epi-
nephrine stimulation tended to decrease the UCP3 mRNA
level, although the changes were not statistically signi¢cant
in four independent experiments (Fig. 2B).
3.3. E¡ects of various L-AR agonists and antagonists on UCP2
and UCP3 mRNA expression in L6 myotubes
It has been shown that L2-AR is the major subtype respon-
sible for various physiological and pharmacological responses
to catecholamines in skeletal muscle [23]. To determine the L-
AR subtype(s) participating in the up-regulation of UCP2 and
UCP3 in L6 myotubes, we examined the e¡ects of various
agonists or antagonists selective for individual L-ARs. As
shown in Fig. 3A, the UCP2 mRNA level was increased by
a non-selective L-AR agonist (isoproterenol), a selective L2-
AR agonist (salbutamol), and also by a L3-AR agonist (BRL
37344) in the presence or absence of carbacyclin. However, it
was not changed by an agonist highly speci¢c to L3-AR
(CL316,243). The isoproterenol-induced increase in the
UCP2 mRNA level was attenuated and completely prevented
by a non-selective L-AR antagonist (propranolol) and a L2-
AR selective antagonist (ICI-118,551), respectively, but not by
a L1-AR selective antagonist (CGP-20712A) (Fig. 4A). Sim-
ilar but less clear e¡ects of L-AR agonists (Fig. 3B) and an-
tagonists (Fig. 4B) were also observed on the UCP3 mRNA
level. The UCP2 and UCP3 mRNA levels were also increased
when the L6 myotubes were treated with forskolin and dibu-
tyryl-cAMP for 24 h and 6 h, respectively, in the presence of
carbacyclin or 9-cis retinoic acid (data not shown). These
results suggested that the epinephrine-induced UCP2 and
Fig. 2. E¡ects of epinephrine on UCP2 and UCP3 mRNA expres-
sion in the presence or absence of carbacyclin and 9-cis retinoic
acid. L6 myotubes were treated for either 6 h (A) or 24 h (B) with
1 WM epinephrine (Epi), and for 24 h with 1 WM carbacyclin (cPGI)
or 9-cis retinoic acid (9-cis RA).
Fig. 3. E¡ects of various L-AR agonists on UCP2 and UCP3
mRNA expression in L6 myotubes. L6 myotubes were treated with
1 WM L-AR agonists for 24 h (A) or 6 h (B) in the 24-h presence
or absence of 1 WM carbacyclin (cPGI). The UCP2 and UCP3
mRNA levels were normalized by the GAPDH mRNA level and
represented as relative to untreated vehicle controls. Values are
means of two experiments. Ve, vehicle; Iso, isoproterenol; Sal, sal-
butamol; BRL, BRL 37344; CL, CL316,243.
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UCP3 mRNA expression was mediated largely through
L2-AR.
3.4. L2-AR in L6 myotubes
To determine the subtypes of L-AR in L6 cells, mRNA
expression of L1-, L2- and L3-AR in L6 myoblasts and
myotubes was examined by RT-PCR analysis. As shown in
Fig. 5A, L2-AR mRNA was detected in both myoblasts and
myotubes, while L1- and L3-AR mRNAs were below detect-
able levels. To con¢rm the functional activity of L2-AR, we
also measured the cAMP level in L6 myotubes after stimula-
tion by various agonists (Fig. 5B). Salbutamol stimulated
cAMP accumulation most e¡ectively, showing a half-maximal
dose (ED50) of 1.1U1036 M. BRL 37344 was much less ef-
fective, and CL316,243 was not e¡ective at all even at higher
doses.
Fig. 4. E¡ects of various L-AR antagonists on UCP2 and UCP3
mRNA expression in L6 myotubes. L6 myotubes were treated with
1 WM isoproterenol (Iso) and 10 WM L-AR antagonists for 24 h (A)
or 6 h (B) in the 24-h presence of 1 WM carbacyclin (cPGI). The
UCP2 and UCP3 mRNA levels were normalized by the GAPDH
mRNA level, and represented as relative to untreated controls. Pro,
propranolol; CGP, CGP-20712A; ICI, ICI-118,551.
Fig. 5. L-Adrenergic receptors in L6 myotubes. A: mRNA expres-
sion of individual L-adrenergic receptor (L-AR) subtypes was ana-
lyzed by RT-PCR for L6 myoblasts and myotubes. B: E¡ects of
various L-AR agonists on cAMP accumulation in L6 myotubes. F
isoproterenol, 8 salbutamol, b BRL 37344, R CL316,243. Values
are means þ S.E.M. for three independent experiments.
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4. Discussion
It has been reported that mRNA expression of UCP2 and
UCP3 in myocyte cell lines such as L6 and C2C12 is up-
regulated by ligands of PPAR and RXR [19,22,24]. This
was con¢rmed in the present study: that is, the mRNA levels
of UCP2 and UCP3 were increased when L6 myotubes were
treated with carbacyclin (a PPAR ligand) and 9-cis retinoic
acid (an RXR ligand). Furthermore, in this study, we demon-
strated for the ¢rst time the direct e¡ects of L-AR stimulation
on UCP2 and UCP3 expression in vitro. The major ¢ndings
were: (1) stimulation of the cells by epinephrine increased the
UCP2 and UCP3 mRNA levels, regardless of the presence or
absence of carbacyclin and 9-cis retinoic acid, and (2) the up-
regulatory e¡ects of catecholamines on UCP2 and UCP3 were
mediated through the L2-AR pathway.
Our results clearly showed that UCP2 and UCP3 were in-
duced in L6 myotubes stimulated by epinephrine, a physio-
logical stimulator of L-AR in skeletal muscle. The e¡ect of
epinephrine was observed even in the absence of carbacyclin
and 9-cis retinoic acid, indicating that L-adrenergic stimula-
tion is able to induce UCP2 and UCP3 independently of the
stimulatory action on nuclear receptors such as PPARs and
RXR. These in vitro ¢ndings suggested that the e¡ects of cold
exposure and L-AR agonist administration on muscle UCP2
and UCP3 so far reported in vivo are attributable, at least in
part, to the direct action of catecholamines (and L-AR ago-
nists) on skeletal muscle. However, it is possible that the
UCP2 and UCP3 induction in vivo is not only due to the
direct action on muscle cells but also is mediated indirectly
through some stimulatory factors. Plasma-free fatty acids are
the most likely candidates for these factors, because they have
agonistic activity for PPARs and their plasma level rises in
response to L-AR agonist administration and cold exposure.
In fact, various types of fatty acids including non-metaboliz-
able fatty acid derivatives have been reported to induce UCP2
and UCP3 in myocytes in vivo and in vitro [18,19,24].
The analyses of mRNA expression and cAMP accumula-
tion in L6 myotubes revealed that L2-AR was the major AR
subtype present in this cell line. Moreover, the epinephrine-
induced UCP2 and UCP3 expression was mimicked by a L2-
AR agonist, but prevented by a L2-AR antagonist. All these
results indicate the pivotal involvement of L2-AR in the ad-
renergic stimulation of UCP2 and UCP3 expression in myo-
tubes. In the present study, BRL 37344 was also e¡ective in
UCP2 induction and also in cAMP accumulation in L6 my-
otubes, although this compound is recognized as a L3-AR
agonist. Considering that a highly speci¢c L3-AR agonist,
CL316,243, was not e¡ective at all, it is likely that the e¡ects
of BRL 37344 may be mediated through L2-AR or other
receptors such as a putative L4-AR. Possible involvement of
an as yet unidenti¢ed L-AR was also suggested by Boss et al.
[17], who observed that administration of BRL 37344 and
CGP-12177 (a L1- and L2-AR antagonist and L3-AR agonist)
increased mRNA expression of UCP2 and UCP3 in skeletal
muscle even in L3-AR-de¢cient mice.
Lin et al. [13] reported in rats that cold exposure increased
muscle UCP3 mRNA rapidly between 6 and 24 h, and UCP2
mRNA later between 1 and 3 days. Similar rapid and tran-
sient induction of UCP3 and delayed induction of UCP2 were
also found in the present in vitro study. These observations
suggest some di¡erent mechanisms and factors are involved in
the regulation of mRNA expression of UCP2 and UCP3.
Yoshitomi et al. [25] demonstrated the presence of the
cAMP response element (CRE) in the 5P-£anking region of
the mouse UCP2 gene, and actual induction of UCP2 by
dibutyryl-cAMP and by 8-bromo-cAMP in 3T3-L1 adipo-
cytes. In addition, Acin et al. [26] reported CRE-like elements
in the 5P-£anking region of the human UCP3 gene. Thus, one
of the possible mechanisms of UCP2 and UCP3 induction in
L6 myotubes is serial activation of L2-AR-linked adenylate
cyclase, cAMP-dependent protein kinase (PKA) and CRE
binding protein, which binds directly to the CRE in the
UCP2 and UCP3 gene promoter regions, although its pres-
ence has not been con¢rmed in the rat. Alternatively, it is also
possible that some additional factors may be involved in
UCP2 and UCP3 induction, as in the case of cAMP-induced
UCP1 expression in brown adipocytes, where cAMP-depend-
ently induced PPAR gamma coactivator-1 (PGC-1) acts as a
coactivator of PPARs. In fact, it was reported that stimula-
tion of brown adipocytes with agonists for L-AR and RXR
increases PGC-1 expression [27], and that overexpression of
PGC-1 induces UCP2 in C2C12 myotubes [28,29]. In prelimi-
nary experiments, to examine the possible involvement of
PGC-1 in myocytes, we measured the PGC-1 mRNA level
in L6 myotubes by RT-PCR analysis. However, unlike in
brown adipocytes, in L6 myotubes the mRNA level of
PGC-1 was not increased by stimulation with L-AR and
RXR, suggesting a di¡erent role of PGC-1 in L6 myotubes.
Since PGC-1 has a phosphorylated site by PKA [27], PKA
may change the activity of PGC-1 in relation to other nuclear
receptors such as PPARs. Further studies are needed to clarify
the mechanisms in the L-AR-mediated UCP2 and UCP3 in-
duction in myotubes.
In conclusion, L-AR stimulation, in addition to PPAR stim-
ulation, up-regulates UCP2 and UCP3 expression in L6 my-
otubes. This may be related, at least in part, to thermogenesis
in skeletal muscle induced by catecholamines in vivo.
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